European Journal of Clinical Investigation · 2009 · 28 citations · 36 references
Life SciencesMolecular BiologyPharmacologyCell SignalingInflammationSignal TransductionAntifibrotic TherapyCollagen DepositionFibrosisAdrenergic AntagonistsAdrenergic Receptor AntagonistsAdrenergic SignalingCollagen DegradationCollagen Degradation InhibitionFibrosis InhibitionFibrotic ChangeMatrix Metalloproteinases In Fibrolysis
BACKGROUND: Transforming growth factor-beta1 (TGF-beta1) is involved in interstitial remodelling promoting collagen synthesis and suppressing collagen degradation by inhibition of collagenases. TGF-beta1 mediates angiotensin II-dependent effects and modulates beta1-adrenergic signalling. To study the effect of neuroendocrine antagonism on TGF-beta-induced hypertrophic and fibrotic phenotype, we treated TGF-beta1 (Cys223,225Ser) transgenic mice (TGF-beta1-TG) with either the beta1-receptor blocker metoprolol (MET), the angiotensin II type I (AT1)-receptor antagonist telmisartan (TEL) or an antibody blocking TGF-beta1 signalling (TGFbeta1-sR-Ab). MATERIAL AND METHODS: Transforming growth factor-beta1-TG mice (8 weeks) overexpressing TGF-beta1 were treated with either TEL (10 mg kg(-1)), MET (350 mg kg(-1)) or a soluble TGF-beta1 receptor antibody (1 mg kg(-1)) for 6 weeks. Morphological analyses of interstitium and cardiomyocytes were related to expression of matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) by immunoblotting and zymography. RESULTS: In TGF-beta1-TG mice, myocardial interstitial total collagen content was fourfold elevated compared to that of controls (P < 0.05) and was lowered under the treatment with TEL (P < 0.05). Protein expression of TIMP-1 and -4 was increased in TGF-beta1-TG but inhibited by TEL (TIMP-1 and TIMP-4) and MET (TIMP-1), while collagenase activity was decreased in TGF-beta1-TG and normalized by treatment with TEL (MMP-1 and MMP-13) and MET (MMP-1) (P < 0.05). Morphometric measurements of cardiomyocyte diameter and area demonstrated similar antihypertrophic effects for all treatment groups. CONCLUSION: The AT1-antagonist TEL reduced myocardial hypertrophy and interstitial fibrosis in TGF-beta1-TG mice by normalizing MMP/TIMP ratio. beta1-Adrenergic inhibition by MET as well as TGF-beta1 antagonism induced antihypertrophic rather than antifibrotic effects. Inhibition of both renin-angiotensin system and beta1-adrenergic system may exert different but synergistic effects to reduce myocardial remodelling.
36
John J.V. McMurray, Jan Östergren, Karl Swedberg et al. · The Lancet · 2003 · 2.6K citations
Medicine, Cardiology, Pharmacology +15
Junichi Sadoshima, Yuhui Xu, Henry S. Slayter et al. · Cell · 1993 · 1.4K citations
Elisabeth Buchdunger, Catherine L. Cioffi, Norman M. Law et al. · Journal of Pharmacology and Experimental Therapeutics · 2000 · 1.3K citations
Medicine, Oncology, Pharmacology +15
John J.V. McMurray, Jan Östergren, Karl Swedberg et al. · The Lancet · 2003 · 1K citations
Medicine, Cardiology, Pharmacology +13